Crystal structures of MMP-1 and -13 reveal the structural basis for selectivity of collagenase inhibitors

The X-ray crystal structures of the catalytic domain of human collagenase-3 (MMP-13) and collagenase-1 (MMP-1) with bound inhibitors provides a basis for understanding the selectivity profile of a novel series of matrix metalloprotease (MMP) inhibitors. Differences in the relative size and shape of the MMP S1' pockets suggest that this pocket is a critical determinant of MMP inhibitor selectivity. The collagenase-3 S1' pocket is long and open, easily accommodating large P1' groups, such as diphenylether. In contrast, the collagenase-1 S1' pocket must undergo a conformational change to accommodate comparable P1' groups. The selectivity of the diphenylether series of inhibitors for collagenase-3 is largely determined by their affinity for the preformed S1' pocket of collagenase-3, as compared to the induced fit in collagenase-1.

[1]  L. Lally The CCP 4 Suite — Computer programs for protein crystallography , 1998 .

[2]  C. López-Otín,et al.  The helping hand of collagenase-3 (MMP-13): 2.7 A crystal structure of its C-terminal haemopexin-like domain. , 1996, Journal of molecular biology.

[3]  D. Wilson,et al.  Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits. , 1997, Journal of medicinal chemistry.

[4]  M. Gehring,et al.  Characterization of the Phe-81 and Val-82 Human Fibroblast Collagenase Catalytic Domain Purified from Escherichia coli(*) , 1995, The Journal of Biological Chemistry.

[5]  H. Birkedal‐Hansen,et al.  Matrix metalloproteinases: a review. , 1993, Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists.

[6]  G J Williams,et al.  The Protein Data Bank: a computer-based archival file for macromolecular structures. , 1977, Journal of molecular biology.

[7]  N. Borkakoti,et al.  Structure of the catalytic domain of human fibroblast collagenase complexed with an inhibitor , 1994, Nature Structural Biology.

[8]  K. Geoghegan,et al.  Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage. , 1996, The Journal of clinical investigation.

[9]  R. Babine,et al.  MOLECULAR RECOGNITION OF PROTEIN-LIGAND COMPLEXES : APPLICATIONS TO DRUG DESIGN , 1997 .

[10]  William G. Stetler-Stevenson,et al.  Matrix Metalloproteinases , 1997, Drugs & aging.

[11]  K. Holme,et al.  Matrix metalloproteinase inhibitors: a structure-activity study. , 1998, Journal of medicinal chemistry.

[12]  H. V. Van Wart,et al.  Understanding the P1' specificity of the matrix metalloproteinases: effect of S1' pocket mutations in matrilysin and stromelysin-1. , 1996, Biochemistry.

[13]  A. Hassell,et al.  Crystal structures of recombinant 19-kDa human fibroblast collagenase complexed to itself. , 1995, Biochemistry.

[14]  M. Browner,et al.  Crystal structures of matrilysin-inhibitor complexes , 1995 .

[15]  A. Ghose,et al.  Hydroxamate inhibitors of human gelatinase B (92 kDa) , 1995 .

[16]  C. López-Otín,et al.  The Role of the C-terminal Domain of Human Collagenase-3 (MMP-13) in the Activation of Procollagenase-3, Substrate Specificity, and Tissue Inhibitor of Metalloproteinase Interaction* , 1997, The Journal of Biological Chemistry.

[17]  C. Rorabeck,et al.  Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. , 1997, The Journal of clinical investigation.

[18]  M. Walid Qoronfleh,et al.  Structure of human neutrophil collagenase reveals large S1′ specificity pocket , 1994, Nature Structural Biology.

[19]  A M Hassell,et al.  Structure of the catalytic domain of fibroblast collagenase complexed with an inhibitor. , 1994, Science.

[20]  H. V. Van Wart,et al.  Purification of human matrilysin produced in Escherichia coli and characterization using a new optimized fluorogenic peptide substrate. , 1995, Archives of biochemistry and biophysics.

[21]  J. S. Johnson,et al.  Inhibition of matrix metalloproteinases by hydroxamates containing heteroatom-based modifications of the P1' group. , 1995, Journal of medicinal chemistry.

[22]  J. Springer,et al.  The NMR structure of the inhibited catalytic domain of human stromelysin–1 , 1994, Nature Structural Biology.

[23]  M. Maccoss,et al.  Inhibition of stromelysin-1 (MMP-3) by P1'-biphenylylethyl carboxyalkyl dipeptides. , 1997, Journal of medicinal chemistry.